Aplodan

Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction [1][2][3][4][5][6].

Product Specifications

CAS Number

[6903-79-3]

Product Name Alternative

Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate

UNSPSC

12352211

Hazard Statement

H302-H315-H319-H332-H335

Target

Biochemical Assay Reagents

Type

Reference compound

Related Pathways

Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/aplodan.html

Purity

99.20

Solubility

H2O : 62.5 mg/mL (ultrasonic)

Smiles

N=C(N)N(C)CCOP(O)(O)=O

Molecular Formula

C4H12N3O4P

Molecular Weight

197.13

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

References & Citations

[1]Botti G, et al. Preliminary report on electrophysiological effectiveness of creatinol O-phosphate (COP) in human subjects. Arzneimittelforschung. 1979;29 (9a) :1491-1494.|[2]Di Maio F, et al. Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial. Arzneimittelforschung. 1979;29 (9a) :1488-1490.|[3]Knippel M, et al. Effects of creatinol O-phosphate on serum enzymes in acute myocardial infarction. Arzneimittelforschung. 1979;29 (9a) :1480-2.|[4]Godfraind T, et al. An analysis of the reduction by creatinol O-phosphate of the myocardial lesions evoked by isoprenaline in the rat. Arzneimittelforschung. 1979;29 (9a) :1457-64. |[5]Marchetti G, et al. Effects of creatinol-O-phosphate (COP) on haemodynamics and cardiac metabolism in conscious and anaesthetized dogs. Arzneimittelforschung. 1978;28 (10) :1708-11. |[6]Olsen JI, et al. A 31P NMR spectroscopy study of Xenopus laevis heart perfused in vitro with creatinol-O-phosphate, phosphocreatine, adenosine triphosphate, fructose diphosphate and ouabain. Pharmacol Res. 1993 Sep;28 (2) :135-51.